Close Menu

NEW YORK – Bionano Genomics has again fallen out of compliance with Nasdaq listing requirements.

According to an April 24 filing with the US Securities and Exchange Commission, the genome mapping firm received a letter from Nasdaq on April 22, stating that for 30 consecutive days, its share price had closed below the $1.00 minimum required for continued listing.

At the close of the market on April 24, shares of Bionano traded at $.35.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.